2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
65
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
5
Non-metastatic Castration-resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Adenocarcinoma
2
Urogenital Diseases
1
Thrombocytosis
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Biochemically Recurrent Prostate Cancer
×
darolutamide
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts